Andy Balo is Vice President of Clinical and Regulatory Affairs, overseeing all of DexCom’s clinical trials, statistical analysis and regulatory submissions. Mr. Balo is widely regarded as an industry expert in regulatory strategies and sits on several FDA panels including cardiovascular, neurological and gastrointestinal as the industry representative. Mr. Balo has been instrumental in bringing several key medical devices to market including a neurological cooling device, mechanical and tissue based heart valves, pacemakers, pacing leads, aortic grafts and electrophysiology mapping devices and has gained approval for over thirty PMA and PMA supplements. Prior to joining DexCom, Mr. Balo held positions as Vice President, Regulatory and Clinical Affairs for Innercool Therapies and Endocardial Solutions.